October 7th, 2026Meta-Analysis Shows Ropeginterferon Alfa-2b Benefit Over Phlebotomy, but Not Hydroxyurea, in Polycythemia VeraPooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.Read more
October 4th, 2026Five Under 5: Top Oncology Videos for the Week of 9/27The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.Read more
October 2nd, 2026OncLive Weekly News Quiz (10/2/2026): Did You Miss Crucial Lung Cancer, Breast Cancer, MDS, and PTLD Updates?Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.Read more
October 1st, 2026Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMMLOral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.Read more
September 29th, 2026Rusfertide Approval Expands Options and Improves Burdens in Polycythemia VeraAndrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.Read more
September 27th, 2026Five Under 5: Top Oncology Videos for the Week of 9/20The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.Read more
September 26th, 2026The OncFive: Top Oncology Articles for the Week of 9/20/2026The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.Read more